QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.

The new healthcare firm will operate across the North American, APAC and European markets, which make up around 90% of the global R&D spend.

Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement ...

SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m.

As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.